ორშაბათი, აპრილი 13, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Botanical

Aloe Vera Leaf Gel

Aloe barbadensis

Also known as: Aloe vera inner gel, Aloe gel, Aloe barbadensis gel

LOW RISK 2.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.5/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Aloe vera inner gel (not the latex) has a reasonable safety profile at normal supplemental doses. The latex (outer leaf) contains anthraquinones with laxative and genotoxic potential. Even the inner gel at high doses may cause electrolyte imbalances and GI cramping. It may interact with digoxin, diuretics, and anticoagulants. Avoid in pregnancy.

Classification

Biological and Chemical Classification

Scientific Name
Aloe barbadensis
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Botanical
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Botanical
Ingredient Aloe Vera Leaf Gel
Scientific name Aloe barbadensis
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Botanical
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Aloe Vera Leaf Gel indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Aloe Vera Leaf Gel
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Aloe barbadensis
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 26 მარ 2026, 14:23

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Biocompatibility and photothermal efficiency of silver palladium (AgPd NPs) and gold palladium (AuPd NP) bimetallic nanoparticles synthesized using Aloe barbadensis Linn. leaf… ↗
    PMID 41835402 ↗
    Journal Cytotechnology
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41835402/
    Lakkakula JR et al.. Biocompatibility and photothermal efficiency of silver palladium (AgPd NPs) and gold palladium (AuPd NP) bimetallic nanoparticles synthesized using Aloe barbadensis Linn. leaf gel.. Cytotechnology. 2026. PMID:41835402.
  2. Observational / other LOW evidence YELLOW
    Draft genome sequence of Enterobacter sp. I4, an endophytic bacterium isolated from Aloe barbadensis Miller. ↗
    PMID 41823384 ↗
    Journal Microbiol Resour Announc
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41823384/
    Nchabeleng MM et al.. Draft genome sequence of Enterobacter sp. I4, an endophytic bacterium isolated from Aloe barbadensis Miller.. Microbiol Resour Announc. 2026. PMID:41823384.
  3. Observational / other LOW evidence YELLOW
    Evaluation and modulation of bactericidal potential of different antibacterial agents against bacterial pathogens from conjunctivitis infections. ↗
    PMID 41792584 ↗
    Journal J Ophthalmic Inflamm Infect
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41792584/
    Arshad S et al.. Evaluation and modulation of bactericidal potential of different antibacterial agents against bacterial pathogens from conjunctivitis infections.. J Ophthalmic Inflamm Infect. 2026. PMID:41792584.
  4. Observational / other LOW evidence YELLOW
    Therapeutic potential of Aloe vera in diabetes mellitus treatment: an update. ↗
    PMID 41779103 ↗
    Journal Saudi Pharm J
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41779103/
    Adil M et al.. Therapeutic potential of Aloe vera in diabetes mellitus treatment: an update.. Saudi Pharm J. 2026. PMID:41779103.
  5. Observational / other LOW evidence YELLOW
    Comparative In Vitro Evaluation of the Antimicrobial Efficacy of Tulsi, Triphala, and Aloe Vera against Streptococcus mutans Relative to Chlorhexidine. ↗
    PMID 41552029 ↗
    Journal Int J Clin Pediatr Dent
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41552029/
    Singh D et al.. Comparative In Vitro Evaluation of the Antimicrobial Efficacy of Tulsi, Triphala, and Aloe Vera against Streptococcus mutans Relative to Chlorhexidine.. Int J Clin Pediatr Dent. 2025. PMID:41552029.
  6. Observational / other LOW evidence YELLOW
    Plant-Mediated Synthesis of Nickel-Doped Cobalt Oxide/Reduced Graphene Oxide Nanocomposites for Combined Antibacterial Activity and EMI Shielding. ↗
    PMID 41427189 ↗
    Journal ACS Omega
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41427189/
    David DA et al.. Plant-Mediated Synthesis of Nickel-Doped Cobalt Oxide/Reduced Graphene Oxide Nanocomposites for Combined Antibacterial Activity and EMI Shielding.. ACS Omega. 2025. PMID:41427189.
  7. Observational / other LOW evidence YELLOW
    Phytogenic Silver Nanoparticles Derived from Ricinus communis and Aloe barbadensis: Synthesis, Characterization, and Evaluation of Biomedical Potential. ↗
    PMID 41301228 ↗
    Journal Bioengineering (Basel)
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41301228/
    Ahsan A et al.. Phytogenic Silver Nanoparticles Derived from Ricinus communis and Aloe barbadensis: Synthesis, Characterization, and Evaluation of Biomedical Potential.. Bioengineering (Basel). 2025. PMID:41301228.
  8. Observational / other LOW evidence YELLOW
    Comparative Clinical and Radiographic Evaluation of Three Different Herbal Extracts in Combination with Calcium Hydroxide as Obturating Materials in Primary Teeth: An… ↗
    PMID 41041409 ↗
    Journal Int J Clin Pediatr Dent
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41041409/
    Amudala N et al.. Comparative Clinical and Radiographic Evaluation of Three Different Herbal Extracts in Combination with Calcium Hydroxide as Obturating Materials in Primary Teeth: An In Vivo Study.. Int J Clin Pediatr Dent. 2025. PMID:41041409.
  9. Observational / other LOW evidence YELLOW
    Clinical Evidence of Traditional Medicines in Modulating the Immune Response and Diabetic Wound Healing. ↗
    PMID 40676793 ↗
    Journal Curr Top Med Chem
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/40676793/
    Dwivedi J et al.. Clinical Evidence of Traditional Medicines in Modulating the Immune Response and Diabetic Wound Healing.. Curr Top Med Chem. 2025. PMID:40676793.
  10. Observational / other LOW evidence YELLOW
    Nature's Remedy: A Comprehensive Review Exploring Herbal Treatments and Natural Approaches for Preventing Acne Vulgaris. ↗
    PMID 40662556 ↗
    Journal Recent Adv Antiinfect Drug Discov
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/40662556/
    Shingari M et al.. Nature's Remedy: A Comprehensive Review Exploring Herbal Treatments and Natural Approaches for Preventing Acne Vulgaris.. Recent Adv Antiinfect Drug Discov. 2025. PMID:40662556.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 2.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.5 / 10

Final GIRI Score for Aloe Vera Leaf Gel. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 2.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
2.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Aloe Vera Leaf Gel

GIRI Score 2.5 / 10

A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge